| Trial ID: | L6878 |
| Source ID: | NCT02092597
|
| Associated Drug: |
Exenatide
|
| Title: |
Safety Evaluation of Adverse Reactions in Diabetes
|
| Acronym: |
SAFEGUARD
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Exenatide|DRUG: Linagliptin|DRUG: Gliclazide
|
| Outcome Measures: |
Primary: Heart rate, 90 days after treatment initiation|Gastric evacuation velocity, 90 days after treatment initiation|Blood pressure, 90 days after treatment initiation|Left ventricular ejection fraction, 90 days after treatment initiation|Intimomedial thickness, 90 days after treatment initiation|Pulse wave velocity, 90 days after treatment initiation|Glomerular filtration rate, 90 days after treatment initiation|Tubular function, 90 days after treatment initiation|KIM-1, Marker of renal damage, 90 days after treatment initiation|Exocrine pancreas function, 90 days after treatment initiation |
|
| Sponsor/Collaborators: |
Sponsor: Charles University, Czech Republic
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
42
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2013-10
|
| Completion Date: |
2016-09
|
| Results First Posted: |
|
| Last Update Posted: |
2018-02-07
|
| Locations: |
General University Hospital, Prague, 128 08, Czechia
|
| URL: |
https://clinicaltrials.gov/show/NCT02092597
|
